Sevoflurane In Acute Myocardial Infarction

• Status: Completed
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Ischemic postconditioning can reduce myocardial injury following myocardial infarction.

A potential pharmacological agent is the anesthetic Sevoflurane. The investigators' hypothesis is that sevoflurane during primary percutaneous coronary intervention (PCI) will reduce infarct size.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lawson Health Research Institute
• Treatments: Sevoflurane

Criteria

Inclusion Criteria:

• First STEMI, presenting within 6 hours after the onset of chest pain

• Symptoms lasting > 30 minutes

• Persistent ST-segment elevation > 0.1 mV in 2 or more contiguous leads

Exclusion Criteria:

• Hypersensitivity to sevoflurane or other halogenated agents

• Malignant hyperthermia

• Cardiac arrest

• Cardiogenic shock

• Previous myocardial infarction or coronary bypass surgery

• Pre-infarction angina

• Heart failure (NYHA III/IV)

• Chronic inflammatory disease

• Severe renal impairment

• Hepatic dysfunction

• Use of Glyburide